"Ocrevus Outshines Competitors as Top Antibody Therapy for Progressive MS: Review"
Ocrevus (ocrelizumab) is the most effective antibody-based therapy for primary progressive multiple sclerosis (PPMS), according to a review study. The medication reduces disability progression, decreases the risk of needing a wheelchair, and improves upper extremity impairment. However, Ocrevus is associated with an increased risk of infection. The other antibody therapies assessed in the study, including rituximab, Tysabri, and Lemtrada, showed conflicting outcomes and were not as effective in treating PPMS. Further research is needed to fully understand the risks and benefits of these treatments for progressive forms of multiple sclerosis.